节奏 is a biopharmaceutical company dedicated to transforming the care of people living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases.

Diseases of severe obesity may result from genetic variants within the melanocortin-4 receptor (MC4R) pathway, a key pathway responsible for regulating weight, that lead to excessive or insatiable hunger or hyperphagia. 节奏’s MC4R agonist, setmelanotide, has been approved in the U.S. and authorized in the EU for certain diseases and is being evaluated in multiple late-stage clinical studies. The company is also leading efforts to improve patient identification and diagnosis through genetic testing and deepen the community’s understanding of the ongoing impact and burden of disease on patients and caregivers.

Meet the 节奏 leadership team and Board of Directors

大卫·米克, MD

主席, President
and Chief Executive 官

詹妮弗·简

Executive Vice President,
Head of North America

Yann Mazabraud

Executive Vice President,
Head of International

猎人史密斯

Chief Financial
官

乔·舒尔曼

Chief Technical
官

Pam克莱默

Chief Human Resources
官

达纳·沃什伯恩

Senior Vice President,
Clinical Development

Elisabeth Crönert-Bendell

Senior Vice President,
Head of Strategy

费海提

Senior Vice President
and General Counsel

节奏 Board Of Directors

大卫·米克, MD

主席

Dr. 大卫·米克, a member of 节奏’s Board of Directors since 2015 and 主席 of the Board since 2017, was appointed President and Chief Executive 官 of the Company in July 2020. Most recently, he served as President and CEO of KSQ Therapeutics for approximately three years.

Ed源泉

Lead Independent Director

Mr. Mathers has served as a member of our Board of Directors since March 2013 and was named Lead Independent Director in January 2021. He joined NEA as a partner in August 2008 and is focused on biotechnology and specialty pharmaceuticals investments.

斯图亚特·阿尔布克尔

Mr. Arbuckle has served as a member of our Board of Directors since July 2019. Mr. Arbuckle is currently the Executive Vice President and Chief Operating 官 at Vertex Pharmaceuticals, where he oversees the global commercial team, which is responsible for the company’s reimbursement and access, 销售, 市场营销, 耐心的支持, and market research, as well as Vertex’s commercial manufacturing and supply chain functions, and other activities that support the approved use of Vertex’s marketed medicines around the world. Mr. Arbuckle also oversees the Human Resources, Corporate Communications and Program and Portfolio Management functions.

卡米尔L. Bedrosian博士

Dr. Bedrosian has served as a member of our Board since December 2020. She serves as EVP and CMO at Ultragenyx Pharmaceutical, a rare disease company with a diverse portfolio of approved therapies and product candidates, where she provides strategic leadership to the clinical development and translational research programs.

珍妮花好

Ms. Good has served as a member of our Board of Directors since June 2019. She is currently the President and Chief Executive 官 of Trevi Therapeutics, a biopharmaceutical company developing nalbuphine ER to treat serious neurologically mediated conditions, which she co-founded in March 2011.

克利斯朵夫R. 琼

Mr. 琼 has served as a member of our Board of Directors since April 2015. He is a seasoned global pharmaceutical industry executive, having held leadership positions in strategy, 金融, business development, M&A and alliances, and managing international operations.

大卫McGirr

Mr. McGirr has served as a member of our Board of Directors since November 2015. Mr. McGirr serves as a director of Insmed 公司., a pharmaceutical company devoted to the treatment of rare diseases; Menlo Therapeutics 公司., focused on the development of serlopitant for the treatment of pruritus (itch) associated with various conditions; and X4 Pharmaceuticals 公司., which is developing therapeutics to improve immune cell trafficking to treat rare diseases.

Lynn Tetrault, JD

Ms. Tetrault has served as a member of our Board since December 2020. She is a global business leader with more than 25 years of experience in the health care industry. Ms. Tetrault spent most of her career with Astra Zeneca PLC, serving in a variety of senior roles, including as EVP of Human Resources and Corporate Affairs for seven years.